LicianPro

CNSY earnings / call

CNSY Q3 2026 earnings call transcript, November 16, 2026

Cerenome, Inc. Third Quarter 2026 Financial Results

Key takeaways from this call : results vs expectations, guidance, what analysts asked

  • SNOW 22%
  • CNSYde 18%
  • Andrew Sims 17%
  • Management 17%
  • Russ Bradley 6%

Management

  • SNOW

    Management

    8 min

  • CNSYde

    Management

    7 min

  • Andrew Sims

    Chief Financial Officer

    7 min

  • Russ Bradley

    Management

    2 min

  • Mark

    Management

    <1 min

Transcribed automatically by Lician from the company's public webcast; it can contain errors and speaker names are best effort.

  1. Prepared remarks10:11
  2. Good day, everyone, and welcome to Serenome's third quarter 2026 financial results and business update conference call.

  3. Q&A10:19
  4. All participants are in a listen-only mode. Following management's remarks, we will open the call for questions. This call is being recorded. Serenome issued its third quarter financial results on Friday. The release is available in the Investor Relations section of Serenome.com. Joining us are Dr. Mark Hedrick, Serenome's President and Chief Executive Officer, Dr. Eric Daniels, Chief Operating Officer, Russell Bradley, President and General Manager of CNSYD Diagnostics, and Andrew Sims, Chief Financial Officer. During today's call, we will make forward-looking statements, including statements about CNSYD orders, payer coverage, and collections, our financial needs, and the timing and outcome of our REOBIC clinical and regulatory milestones. These statements reflect our expectations as of today. Actual results may differ materially. Please refer to Friday's release and our SEC filings, including the risk factors described there. We will undertake NOAA to update these statements except as required by law. Dr. Hedrick you may begin.

  5. Thank you Jamie.

  6. Good morning everyone and thank you for joining us. With me today are Russ Bradley, Eric Daniels, and Andrew Sims. On this morning's third quarter call in addition to our usual quarterly reporting, we wanted to highlight data from our RESPECT-LM trial, which we presented last Friday at the Society for Neuro-Oncology annual meeting in Philadelphia, as well as provide some interim commercial progress we've made with CNSYDE since our last call. But I'd first like to start off with a few general comments. First of all, I'm very pleased to announce that we've strengthened our leadership team with three important appointments. First, Samantha Foulkes has joined us as Vice President of Sales. We are on track with our commercial goals thus far with a small internal team. and no dedicated sales staff. Samantha is tasked with building our commercial team as we plan for strong growth in 2027. Second, Ronnie Andrews, a member of our Board of Directors, has agreed to join the management team as our Chief Business Officer. Ronnie brings 35 years of experience across life sciences and diagnostics. He will focus on helping the company capitalize the business as well as expanding on our therapeutic and diagnostic partnerships. Third, Dr. Eric Daniels has been promoted to Chief Operating Officer. In this role, Eric will take on a broader operational mandate and support the increasingly integrated nature of our work across diagnostics, therapeutics, and advanced data analytics.

  7. As mentioned, our CNSY diagnostic business remains on track to meet the goals we set at the start of 2020. We expect to exit 2026 at an annualized run rate of about 1,250 tests per year, at our 150 million total covered lives goal for our lead diagnostic cell enumeration assay. We also remain on track to... ...to secure Medicare reimbursement in the first half of the year. Russ will go into the details and walk through our plans for the rest of the year and give a preview of 2027. We are also on track to meet our aerobic clinical development goals. Most notably, we've closed enrollment in our RESPECT GBM Phase 2. trial and are making steady progress enrolling our RESPECT-LM multi-dose optimization trial. Eric will discuss the RESPECT-LM data presented at SNOW last Friday. We expect full top-line data from both trials, GBM and LM dose optimization, in mid-2020. So now I'd like to turn the call over to Eric to walk through the clinical update and take you through the data presented at SNOW. Eric?

  8. SNOWManagement

    Thank you, Mark.

  9. Our lead asset, Rayobic, is a precision or targeted radiopharmaceutical for central nervous system cancers that we are advancing in the... ...treatment of leptomeningeal metastasis, recurrent glioblastoma, and pediatric malignant gliomas. I'd like to take this quarterly opportunity to review our 2026 objectives and progress for Rayobic as follows. Objective number one is to define the optimal dose interval for Rayobic in the Respect LM Phase II trial. with an anticipated interim data readout in the second half of 2026. This objective has been met with interim data presented, as Mark mentioned, at the Society of Neuro-Oncology meeting this past weekend and press release this morning. I will take a moment to review the ongoing study, interim findings, and our plans ahead. In this multi-dose study, we administer Rayovic, our liposomal-targeted radiopharmaceutical, directly into the LM compartment through an implanted port or reservoir, thus bypassing the blood-brain barrier. In this dose-optimization phase, we are evaluating various doses and various intervals between three... ...repeated administrations of Rayovic and measuring how much radiation reaches or is absorbed in the LM compartment over the course of the full treatment. The interim multi-dose findings. At the 2026 Society of Neuro-Oncology Annual Meeting, we reported on the first 10 patients in this study, and here are the highlights.

  10. Patients were enrolled with a confirmed diagnosis of LM with a mix of primary tumor types, including three breast, one lung, four melanoma, and two ovarian. Repeated doses is working as designed. The 10 patients were treated across three cohorts, and dose escalated. This condition is continuing as planned. To date, one patient received three 26.4 millicurie doses for a total of 79.2 millicuries administered. That is more than the 66 millicurie maximum feasible dose from our earlier phase one study, with no observed dose. Limiting toxicity. Safety is clean so far. As I just mentioned, there have been no dose limiting toxicities and no side effects that led to a patient to stop treatment. The one grade three treatment related event was nausea, which is well known in intrathecal delivery that resolved in five days. The one serious adverse event, shortness of breath, was judged unrelated to the drug. Dosimetry is predictable from dose to dose. Within each dose, the radiation per millicury varied by only 8% across repeat doses. A single 13-point 2 millicury dose delivers about 40 gray to the fluid space around the brain, also consistent with our earlier study. Importantly, bone marrow exposure, which is the cause often of dose-limiting cytopenias, stays very low. Early disease control stigma is present, still descriptive. Only one of 10 patients had leptomeningeal progression through MRI documentation at 7.5 months. Three patients died of their primary cancer, not the leptomeningeal disease, and six remain on study. Several patients' CSF tumor count

  11. fell to zero and stayed there. Overall, there was durable suppression of CSF tumor cell counts. What's next and what to watch? Enrollment continues in the shorter interval and higher dose cohorts to define a recommended multiple dose regimen. Formal efficacy endpoints response rate, neurological free, excuse me, progression-free survival, overall survival are not yet accessible given we are still early in the trial timeline. So what is the path to approval for Rayobic and LM? Well, just as important as the initial data is the next steps. At the end of our phase one meeting in November 2025, the FDA aligned with our current ongoing dose optimization design for multiple doses of Rayobic. At the completion of the dose optimization study, we will meet with the agency with the body of safety, dosimetry, and preliminary efficacy. Data and agree on a randomized phase two study. We have alignment with the FDA. This next study will include a dose randomization strategy, and we are contemplating an adaptive design to potentially include a control arm. Our aim is to emerge from the phase two randomized study with a robust data set capable of demonstrating substantial evidence of safety and effectiveness. Candidate primary endpoints subject to change include neurological function and overall survival. I'll now turn our attention to recurrent glioblastoma. Our objective number two in 2026 was completing enrollment in the RESPECT GBM phase two

  12. trial for glioblastoma. and conducting an end of phase two meeting with the FDA with the goal of aligning on a pivotal trial design with data expected in Q4 2026. The objective of completing enrollment has been met this past quarter. On October 29th, we announced we have closed phase two enrollment after treating 32 patients at the recommended dose. The original plan was 34, yet after reviewing the statistical impact, we determined that closing at 32 would have minimal effect on the power of the planned analysis. With ongoing data maturation and database cleaning, we expect to report top-line data from this study in mid-2027. Next steps following the data... the readout, including an end-to-Phase II meeting with the FDA, will be data-dependent. Objective number three is to begin enrollment in the RESPECT Pediatric Brain Cancer Phase I trial. This objective has been met as the trial is open and currently enrolling. We look forward to keeping people updated on the trial progress in 2020. Objective number four is to complete commercial manufacturing scale-up for Rayobic. This objective also remains in progress and on track to be completed by the end of the year. The recommendations from our Type C meeting with the FDA regarding purification, qualification, and impurity characterization are all on schedule. to be completed by the end of the year, and method transfer is in process to a CDMO, and the Q4 audit is planned by the end of the year. We maintain that manufacturing scale and supply of Rayobic will readily support the clinical early, excuse me, early commercial activity. In addition,

  13. to our stated objectives, we also announced preclinical data outlining a dual mechanism of action in aggressive epithelial ovarian cancer preclinical models. The highlights include a dual MOA. Rayobic, in addition to its radiopharmaceutical properties, provides targeted local radiation that induces lethal DNA damage and apoptosis within 24 hours while simultaneously remodeling the tumor microenvironment. Why is this important? For immune activation, the therapy shifts immunologically cold tumors to hot ones by triggering innate immunity. And reducing immunosuppressive signals like IL-10 and macrophage activity, both of which are elevated in tissue and ascites. What does this ultimately mean? There is combination potential. Pairing Rayobic with an anti-PD-1 checkpoint blockade substantially boosted anti-tumor efficacy compared to single tumor. Or single agent, excuse me, approaches. This dual mode of action opens the door to a whole host of combination potentials with Rayobic, both within and even outside of the CNS. So, in summary, three of our four objectives for radiotherapeutics in 2026 are completed, and the fourth remains on track for complete... by the end of the year. We will continue to advance Rayobic, and we look forward to reading out top-line data for both the ongoing LM multidose and GBM studies in mid-2027.

  14. Thank you for your time, and I'll hand the call over to Russ for the CNSYde update.

  15. CNSYdeManagement

    With our September 30 update, CNSYde has moved from submitting claims to recognizing revenue and receiving payments. We recognized about $0.7 million of net diagnostic revenue in the third quarter, and commercial payers began paying our claims in October. Andrew will take you through the next. numbers. October was our strongest month so far. We were up about 15% over our third quarter monthly average, bringing us to 512 tumor cell enumeration tests year to date. Most of these, of course, are back-end loaded in a year, which is consistent with our expected ramp. Growth is coming from three separate drivers, new account activation and physician adoption, growth in patient monitoring, and an expanded test menu. First, I'll go through the new accounts and physicians.

  16. 46 institutions and 45 providers are now ordering up from 13 at the start of the year. Growth is broadening outside our largest accounts. October test growth was 22% above the third quarter monthly average. Behind that, we have a backlog we are clearing. Specifically, we have 34 more institutions in line to be onboarded. Converting those will be the early focus of our growing commercial team. Second driver, patient monitoring. Patient monitoring or repeat testing of the same patient patient. Over time, it's supported by the current National Comprehensive Cancer Network or NCCN guidelines for cancers of the central nervous system and support this practice for patients on selected leptomeningeal treatment pathways. They recommend reassessing the CSF every four to eight weeks. Every monitoring test comes from a new specimen and is a billable event from a patient already in our care. While still early into the launch timeline, nearly one in four patients has been tested more than once and 23 have been tested four or more times. Also, a growing number of our ordering institutions now use CNSY to monitor their patients. Each repeat order signals that physicians find the result useful in managing care. Driver number three is expanding the test menu. On October 12th, we launched the CNSY CSF. molecular profile for solid tumors and hematological malignancies, providing both RNA and DNA profiling

  17. from cerebral spinal fluid. Tumor cell enumeration tells a physician where the tumor cells are present and how many. Molecular profile characterizes the alterations in that cancer. And so physicians can order either or both from the same patient role. And the first molecular profiles were ordered and recorded in October, achieving a menu expansion goal we set in January of 2026. Behind the launch of the molecular profile last month, we are readying the launch of additional CSC. It's a cellular biomarkers to further characterize the tumor cells. Market access. When we started the year, CNSY had contracted coverage for about 67 million lives, and we set a goal of reaching 150 million by year's end. Today, we stand at approximately... 190 million covered lives, or about 80% of U.S. private payer coverage. Our recently announced agreement with Aetna is our first national agreement to include contracted rates for both tumor cell enumeration and molecular profiling. So a physician can now order... both profiling tests from the same CSF sample in network. On Medicare coverage, our proprietary billing code for tumor cell enumeration took effect on July 1st, and our enrollment is now complete. Medicare reimbursement is a complex multi-step process... And we're tracking for Medicare reimbursement in the first half of 2027. So now looking ahead, for the rest of this year, our priorities are converting onboarding accounts to first orders and growing the molecular profiling base alongside our proprietary tumor cell enumeration test. And of course...

  18. building collections and claims that we submit. In 2027, we will push on all three of these drivers. On adoption, we are building out our field sales team. Their first priority is converting the 100 signed access agreements and the 34 onboarding accounts into active order centers. And bringing multiple ordering physicians on board at each one. On monitoring, our goal is to make repeat CSF testing a routine part of how physicians follow their patients on treatment. This is consistent with the NCC and guidelines. We will work with ordering physicians to build CNSY into their monitoring. schedules, and we will continue generating the clinical evidence that supports monitoring, including the CSF data from our own RESPECT-LM clinical trial for Reogic. On the expanding menu, our breast cancer cellular protein expression assays are now in validation testing. And we plan to launch them commercially in 2027. With tumor cell enumeration, molecular profiling, and protein expression available from a single CSF collection, oncologists will be able to confirm disease, characterize it, and follow it over time with one partner. And we'll be able to run more tests on each specimen. Underpinning all three drivers, we expect to secure Medicare reimbursement in the first half of 2027, continue presenting clinical utility evidence to payers, and to build on our collection experience across the full see inside menu. Put simply, adoption brings us more physicians and patients, monitoring brings more tests per patient, and the expanding menu brings us more tests per specimen. Each one of these compounds on the others, and that is what we are building towards in 2027.

  19. CNSY also supports our therapeutic program. In the RESPECT-LM trial, we use it to follow CSF tumor cell counts in patients receiving Rheovic, which Eric just reviewed. And with that, I'll turn it over to Andrew for the financial update.

  20. Andrew SimsChief Financial Officer

    Thanks. Let me start with CNSY, noting that there are three separate figures to keep in mind. The first is gross billings. In Q3, we submitted claims for 222 tests with gross charges of approximately $1.55 million. That figure reflects list pricing. The second is net diagnostic revenue. We recognized $0.7 million in the quarter. In determining net revenue, we estimate the amount we expect to receive after contractual adjustments and price concessions. The third is cash. In October, we received approximately... ...$0.1 million in cash collections. Collections accelerate as our submitted billings ramp. As more claims are processed, we'll better define payer reimbursement behaviors and determine what, if any, adjustments we may need to make to revenue estimation. These early and positive collections are an important first step in that process. On our September call, we discussed what an annualized gross billing run rate might look like as order volume increases and the menu expands. That calculation used list prices in a... ...assumptions about which tests physicians would order based in part on the 11,000 performed tests by CNSY's original developer. For modeling purposes, the additional inputs are the actual mix of tests ordered, the payer responsible for each claim, negotiated claim rate, and... ...collection timing. We now have some experience submitting claims. Yet, as I mentioned, we are still early in building the collection history needed to estimate those inputs more reliably. As I said into September, until we have payer experience in a collections history, we will use gross billings as the logical way...

  21. to communicate business progress ahead of a revenue or cash number. In terms of actual revenue guidance, we expect to have enough data points once we have two to three quarters of billing and collections in place to a guide to a go forward revenue estimate. Until then, we will focus on gross billings. Today, we reaffirm our guidance. We expect to exit 2026 at an annualized gross billings run rate of approximately $10 million to $12.5 million. Based on 2026 commercial patents observed thus far, in 2027, we expect testing, billing, and funding. Collections to accelerate and materially offset CNSY's cash burn by the second half of 2027. If current trends continue and with a sales force, we could potentially start to see positive contribution late in 2027. Turning to our consolidation. Total revenue for the quarter was $0.7 million, all from diagnostics. In the same quarter last year, revenue was $1.4 million, all from grants. Cost of revenue this quarter was approximately $0.9 million. Research and development expense was $2.1 million.

  22. Primarily because CNSY moved from development into commercial operations, so validation study costs from last year did not recur. Selling, general, and administrative expense was $5.2 million, up from $3.4 million. The largest contributor to the year-over-year... increase in SG&A was the expansion of our team, including the CNSY commercial build-out, which increased total compensation costs. Recruiting costs also rose as we added staff. Facility rent and stock compensation also contributed. Looking at the first... By months, we recognize 1.4 million in grant revenue, in addition to the 0.7 million in diagnostic revenue. Grant revenue was 3.8 million in the comparable period last year. This helps explain why the year-over-year revenue comparison looks different from the progress we are seeing in diagnostics. Our operating... Net loss was 7.5 million compared to 4.5 million a year ago. Net loss was 8.7 million, or $1.14 per share, compared with 4.4 million, or $1.03 per share, in last year's third quarter. This quarter also included 1.2 million in net financing expense. September, with 4.9 million in cash, cash equivalents and investments, compared with 8.6 million as of June 30. However, we raised just under 4 million in October, and continue to have access to the 20 million royalty and financing facility we announced in September. This combination, if fully accessed, extends a runway into 2028.

  23. Mark, I'll turn it back to you.

  24. Thank you, gentlemen.

  25. When we laid out our goals for the year, two key milestones we wanted to accomplish were giving patients more access to CNSYD and completing enrollment in a recurrent glioblastoma study. Both are achieved. and the team has made solid progress across the board. For CNSYD, the next measures to watch are orders from the centers we brought on board and will bring on board through the year, cash collected on the claims we submit, as well as Medicare reimbursement. For AIOBIC, we expect top-line data from both glioblastoma Phase II in the LM multi-dose mid-year in 2027, and we plan to start a randomized Phase IIb study in LM in the second half of 2027. I just want to end by thanking the patients and the families who participate in our trials and to the

  26. clinical teams who care for them. Operator, Jamie, we're now ready for questions. In terms of questions, I'll take the initial question and then hand it off to any of our team as needed. At this time, we'll begin the question and answer session. To ask a question, you may press start and then one using a touchtone telephone. To withdraw your questions, you may press star and two. If you are using a speakerphone, we do ask that you please pick up the handset prior to pressing the keys to ensure the best sound quality. Once again, that is star and then one to ask a question. We'll pause momentarily to assemble the roster.

  27. Operator

    Our first question today comes from Sean Lee from HC Wainwright. Please go ahead with your question.

  28. Question · H.C. Wainwright

    Sean LeeAnalyst · H.C. Wainwright

    Good morning, guys.

  29. Congrats on the great results. I just have a couple of questions on the LM data. When do you expect to present the next update from this study? And will we be able to see things like the overall survival, the renal response, and also the quality of life, which I know is very important for these patients?

  30. Management

    Hey, Sean, thanks for the question. Eric, would you mind addressing that, please?

  31. Management

    The next readout you can expect will be the top line data from this study. So we will enroll targeting another 10 to 15 patients. And having that enrollment plus maturation of the data, you can expect that in mid-2027. And yes, it will include, by that time, measures of progression-free survival and median overall survival, as well as neurological survival. Function and quality of life. Okay, great to hear that. I'm looking forward to those. And my next question, my second question is on the correlation in LN progression between MRI and the CSF tumor cell via suicide.

  32. Management

    How well do those results correlate? And is the CSI monitoring being able to, I guess, predict progression for these patients?

  33. Management

    LN progression is measured along three traditional. Paths by criteria. Clinical suspicion, number one. Number two, MRI or imaging. And number three, traditionally cytology or CSF evaluation. They're all somewhat squishy at some level. Dominantly MRI and oftentimes related to the amount of tumor burden. So to answer your question, they often would correlate, but not entirely on a one-to-one or perfect correlation, which is why they have various degrees of sensitivity. And specificity. So the CNSY test or the tumor cell enumeration has a higher sensitivity and specificity. And when we look at the data, at least from the first 10 patients, you do see a durable suppression. I will refer you to an example on the poster that's available on our website. Where you do see the one patient who did progress with an LN diagnosis, and you can see their tumor cell count starting to rise prior to the progression.

  34. Question · H.C. Wainwright

    Sean LeeAnalyst · H.C. Wainwright

    Understood. That sounds very helpful. My last question is on the comparison meeting, the multi-tumor. Those in the single dose. So the one reported patient who received the three cumulative doses, the three 26 military doses seems to have a cumulative similar to what the higher cohorts received in the single dose cohort study. So I was wondering how do these compare in terms of, you know, both. Activity and toxicity.

  35. Management

    That is really one of the big takeaways we would like people to see from these first 10 patients, which is the feasibility of doing fractionation. In other words, going back to the phase one study. The maximum feasible dose was 66 millicurie, as I mentioned. There was an additional cohort that had been administered 75 millicurie. Those were single-dose administrations. In both of those cohorts, there was a dose-limiting toxicity related to the marrow.

  36. Management

    In this multi-dose study, the hypothesis was, by fractionating that, you could actually deliver more millicuries, more absorbed radiation, cumulatively, without the dose-limiting toxicity. To be clear, we've had actually multiple patients receive three. However, we've just had one, and that's just been the natural progression of the enrollment. That's already received, numerically, the 79.2. So we've already exceeded the maximum amount of millicury that was administered from the Phase I, 79 greater than 75. There have been no dose-limiting time. toxicities. And when we look at the amount of radiation in the marrow, it is dramatically lower than it was for those two patients that had dose-limiting toxicities that I mentioned previously or referred to in the Phase I. The bottom line is that we've broken the ceiling from Phase I and, to date so far, feel very confident. We could administer, ultimately, more radiation, get and deliver more absorbed radiation, and avoid any of the dose-limiting toxicities that are known for not just Rayovic, but any radiopharmaceutical.

  37. Management

    Got it. That makes it much clearer.

  38. Operator

    Thank you again for taking my call. I'll jump back in the queue. Thank you. Once again, if you would like to ask a question, please press star and 1. To withdraw your questions, you may press star and 2.

  39. Our next question comes from Ed Wu from Ascending Capital. Please go ahead with your question. Yeah, congratulations on...

  40. Question · Ascending Capital

    A
    Ed WuAnalyst · Ascending Capital

    All the progress. As you build out your sales team for CNSY, have you identified how many salespeople you think you may need and how quickly will they be able to ramp up?

  41. MarkManagement

    Hey, Ed, it's Mark.

  42. Question · Ascending Capital

    A
    Ed WuAnalyst · Ascending Capital

    Thank you. Russ Bradley, would you mind taking that question, please? Yeah, sure, Mark.

  43. Russ BradleyManagement

    Hi, Ed.

  44. Okay, so the, yeah, we do have an initial tranche, I guess I'd call it, of salespeople. We've looked at where the bulk of the ordering activity is for CNSY and where the major centers are that treat. These kinds of patients. And initially we're going to cover the U.S. with four salespeople and get them started. We're actually recruiting right now. So we'll get them started and onboarded and trained. And I think we have some plans through the year based on continuing to grow and look at those territories to expand that commercial team to make sure that we're getting the efficiency and the effectiveness and coverage that we're looking for. In terms of how long it takes to ramp, the way we're profiling. these professionals is that they have experience in precision oncology. So they'll already come in with the experience to be able to work in the role as we've defined it. And. We have a pretty extensive training program ready to go to get them up and going. We, we think there'll, they'll be effective within 90 days in the space, but you know, they'll be out there introducing themselves to accounts that we have and some of the onboarded accounts that I, that I was referring to my remarks, but yeah, I think it's, it's. The initial start, we've also looking to hire the supporting team because obviously the people in the field need support as well. And those are, those interviews and that recruiting is well underway. So it's, it's a, it's a plan right now to deliver a full package of commercial effectiveness in Q1. So I'm expecting.

  45. In Q1 that we'll have, you know, feet on the ground, already growing our business and impacting, you know, the number of accounts that we can bring on board. So hopefully that, that answers your question.

  46. Yes, it does.

  47. Thank you very much.

  48. Question · Ascending Capital

    A
    Ed WuAnalyst · Ascending Capital

    And my last question is on the lab. Uh, capacity. Is there, uh, any, uh, issues potentially as you ramp up your tests in terms of how much tests you can process? Yes. So Mark, do you want me to take that? Please. Yeah. So, so we, uh, recently moved. Our lab, uh, for that very purpose of, of expanding capacity. So in September, we moved to our new facility at Levitt Green so that we could expand capacity. And we've got an eye on a critical eye on making sure that we're able to grow our test volume. So right now our capacity is significantly in advance of our, of our current volume. Uh, we think the capacity in the current site, uh, and, and our future expansion plans, uh, is out through, you know, probably 10 years. So I don't believe capacity constraints are going to stop our growth. I mean, we've had a very deliberate approach to making sure that, uh, we've got the capacity to, to meet the demand that we're seeing and, you know, for years into the future. So. Uh, happy to update on that, but at the moment, we don't foresee any capacity issues. Great. Thank you. And I wish you guys good luck. Thank you.

  49. Management

    And at this time, we do have a written in question. Uh, and I'd like to turn the floor over to Andrew for that question.

  50. Andrew SimsChief Financial Officer

    Thanks, Jamie.

  51. Question · Ascending Capital

    A
    Ed WuAnalyst · Ascending Capital

    Uh, so the question is, uh, can management outline the path to a positive contribution from the CNSY diagnostic and, um, outlined, uh, expected timeline to achieve that? So Mark, if it's, if it's okay, I'll take that. Uh, sure. Go ahead.

  52. Thanks, Andrew.

  53. Management

    So as, as I laid out in my prepared comments, um, we, we, we guided to exiting the year and gross billing of 10 to 12 and a half million dollars, uh, of, of, of gross revenue, um, for kind of simplification and to provide kind of straightforward. Um, you know, we, we, we plan to, or we're seeing initial collections of approximately 50% of that number and we expect that to grow over time. Um, as we look ahead in to 2027 with the growth of the sales force, uh, continued growth, um, as Russ laid out, both in terms of. Uh, core TCE sales together with expanding menu items, um, for, for the, for the overall sample, we expect that gross billing revenue number to double in, uh, 2027. The current, um, to, to put it in the range of 20 to 25 million of gross revenue by. The end of 2027, uh, the overall, uh, burn for CNSY currently is about 10 million a year. So you can see that on pretty, pretty straightforward math that kind of exiting forecast revenue number at the end of 27, um, equates to more than. equates to the, the overall cash burn that we project in 2027. So, um, you know, we, we expect to, to hit that positive contribution, um, at that, um, higher revenue number, um, that I just outlined. So on that, Mark, I'll turn it back over to you. Okay. Great. Thank you. And, uh, just to follow on from that, I think at this point, we're not ready to, to forecast and provide guidance for 2027. I think we'd like to have another, uh, another month or two of operational, uh, information that we can, you know, we can refine our, our, our, um,

  54. Management

    forecast, but I think you have enough information to see where the business is going. So I think I'd just go ahead and conclude today.

  55. Question · Ascending Capital

    A
    Ed WuAnalyst · Ascending Capital

    Thank you for the questions.

  56. Operator

    Thank you to everyone that's joining us today online for your interest in Cyrano. And we'll continue to update you closely on progress along the way for the remainder of 2026 and into 2027. Thank you. And with that, we'll be concluding today's conference call and presentation. We do thank you for joining. You may now disconnect your lines.

ReplayListen